All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: ATB-346
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Nuance Pharma
Deal Size: $100.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement February 09, 2021
Details:
The license provides Nuance with exclusive rights to commercialize otenaproxesul in China, Hong Kong, Macau, and Taiwan, representing approximately 10% of the worldwide pharma market.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Data suggest Montelukast may inhibit mental decline, higher doses optimal for clinical trials assessing impact on neurological disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ezogabine
Therapeutic Area: Neurology Product Name: XEN496
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
Xenon has received a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), which recommends the granting of an orphan medicinal product designation for XEN496 for the treatment of KCNQ2-DEE.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Bloom Burton Securities
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 09, 2020
Details:
The net proceeds of the Offering will be used to fund activities required for large market partnering and in support of the Phase 3 program for ATB-346, for business development activities, and for advancing the other drugs in the Company’s pipeline including ATB-352.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Conference will focus on the recent positive results of the Phase 2B dose-ranging, efficacy study for ATB-346. Management will provide a brief summary of the results followed by a Q&A session for analysts.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
The 150 mg dose of ATB-346, although not powered for statistical significance, demonstrated more potency than expected and the lowest effective dose is still to be established.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
Details:
Antibe's partner, Veristat, was able to complete the Phase 2B dose-ranging, efficacy study for ATB-346 and capture all patient data without compromising the size and integrity of the study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dronabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
Details:
The receipt of the DEA Schedule 1 license is a significant milestone in the advancement of the Plenitude trial and ultimately getting QIXLEEF™ into the market.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2020
Details:
The study is evaluating the effectiveness of ATB-346 in reducing osteoarthritis (OA) pain compared to placebo in 360 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dronabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2020
Details:
The FDA validated Tetra’s nonclinical program proposed to support clinical trials in non-cancer pain indications and the New Drug Application.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
